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ABSTRACT
Objective: The objective of this selective EBM review is to determine whether or not Sinupret
(BNO 1016- herbal combination) is an effective treatment for the symptoms of acute and chronic
rhinosinusitis compared to non-treatment in male and female adults ages 18-75?
Study Design: This is a systematic review of three randomized controlled trials (RCTs)
regarding Sinupret treatment for sinonasal symptoms. All RCTs were published in the English
language in peer-reviewed journals in 2011, 2015, and 2017.
Data Sources: Three randomized controlled trials were found using PubMED and CINAHL
databases.
Outcomes Measured: Symptom relief of acute and chronic rhinosinusitis was measured via
major symptom score (MSS) of rhinorrhea, post-nasal drip, congestion, headache, and facial
pressure by participants (measured by mean change from baseline). Assessment of responders vs.
non-responders to treatment as designated by “cured/improved” vs. “unchanged/deteriorated.”
Improvement of olfactory function per phenylethanol odor testing as well as odor discrimination
and identification testing.
Results: Jund et al.3 showed a greater decrease in acute viral sinusitis symptoms (MSS decrease)
with Sinupret treatment than with placebo-treated group (p<0.0001) as well as a NNT of 10.
Palm et al.6 showed similar reduction in MSS in the use of Sinupret for chronic sinusitis
(p<0.0015). Reden et al. 7 showed improvement in olfactory function in sinusitis patients
withdrawing from prednisolone with the use of Sinupret, but failed to show statistical
significance (p=0.67).
Conclusions: Two of the three studies reviewed studies revealed that Sinupret, herbal
combination, can be used as an effective treatment in adults 18-75 years old for decreasing the
symptoms of acute viral and chronic sinusitis at a faster rate than no treatment at all. Multiple
studies suggested expanding the study population beyond German participants.
Keywords: sinusitis, rhinosinusitis, herbal treatment, common cold

Boyle│Sinupret-Herbal Treatment & Sinusitis 1
INTRODUCTION
Acute viral rhinosinusitis (AVRS) and chronic rhinosinusitis (CRS) are common diseases
that involve inflammation of the nasal passageways and paranasal sinuses. They lead to the
familiar symptoms of rhinorrhea, congestion, facial pain, fatigue, post-nasal drip, and headache.1
Rhinosinusitis is a condition accounting for more than 16 million visits to primary care
physicians in the United States.2 It is a major contributing disease to the overprescribing and
overuse of antibiotics.
AVRS is also known as the “common cold” and is designated as the most prevalent
infectious disease in the United States, causing an average of two to three episodes per year in
individual adults.3 It is usually caused by viruses- rhinovirus, coronavirus, and influenza virus
being some of the most common.4 Being so prevalent, AVRS is a major cause of increased
health care costs as well as lost productivity costs in the US. It accounts for 40% of total time
lost from jobs in employed persons and an estimated $39 billion annually.2 CRS occurs in
individuals in which sinusitis symptoms lasts greater than 12 weeks and was found to effect 216% of U.S. adults.5 CRS can develop as a sequela from multiple acute infections, chronic
autoimmune processes, or allergies.6
No gold standard of treatment exists for AVRS and CRS. Common methods used are for
symptomatic treatment only. These include over-the-counter analgesics, antipyretics, irrigation
(nasal saline sprays and Neti Pots), intranasal corticosteroids, antihistamines, decongestants, and
mucolytics (guaifenesin). As previously stated, antibiotics are overused in the treatment of nonbacterial sinusitis. One study by Sharp et al7 researched and tracked medical prescriptions for
sinusitis diagnoses in primary care settings; their findings suggested that although only 3-5% of
sinusitis cases have bacterial causes, four out of five patients were treated by with antibiotics.
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This denotes sinusitis as a major contributor to antibiotic resistance. There are many
symptomatic treatments for sinusitis, however, there has been a demand for more naturally
derived remedies that can be obtained over-the-counter at a low cost.
With sinusitis being incredibly common and lacking a gold standard treatment, it has
remained a popular area of research. Sinupret, BNO 1016, is a new herbal remedy for sinusitis
that was released in 2012 from Binorica AG Pharmaceuticals in Germany3,9 The company has
released many herbal formulations in the past for the treatment of bronchitis, tonsillitis, and flu
prevention; they are used as over-the-counter treatments throughout Europe. Sinupret is an oral
tablet, containing an herbal dry extract combination of gentian root, primula flower, sorrell herb,
verbana herb, and elder flower. The manufacturers of Sinupret report that it can be used to
decrease the duration of symptoms of AVRS and CRS by enhancing the body’s natural defense
mechanisms while reducing inflammation and excess mucus production in the nasal cavity.6,9
The company claims that the herbal combination is effective in that: primula delivers antiinflammatory and expectorant properties, gentian root provides an anti-inflammatory effect,
elderberry provides an expectorant effect, sorrel herb delivers anti-inflammatory and antibacterial effects, and that verbana herb provides expectorant and anti-viral properties.9 However,
the sources of these claims were not listed by Binorica. This systematic review is designed to
evaluate three randomized control trials which studied the use of Sinupret herbal combination in
patients with sinusitis.
OBJECTIVE
The objective of this selective evidence based medicine review is to determine whether or
not Sinupret (BNO 1016- herbal combination) is an effective treatment for the symptoms of
acute and chronic rhinosinusitis compared to non-treatment in adults ages 18-75.
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METHODS
Criteria: All three RCTs examined populations of adults with diagnosed AVRS/CRS as
well as anosmia. The three studies were deemed reliable as they were randomized, conducted in
a double-blind, placebo controlled manner, the trials were appropriate length for the AVRS/CRS
disease course, and the intervention and control groups were similar prior to starting the
interventions. Inclusion criteria for this systematic review included double-blind randomized
control trials, evaluating the Sinupret intervention in AVRS/CRS specifically, articles published
in English, and the need for the RCTs to be published 10 years prior to February 1st 2018. The
intervention used in these studies, Sinupret, 160 mg oral tablet three times a day, was compared
in efficacy to an oral placebo pill taken three times a day. Outcomes measured included mean
reduction of symptoms of AVRS/CRS using the Multiple Symptom Score (MSS), determining
responders vs. non-responders to Sinupret treatment, and through olfactory function testing (TDI
score).
Data Sources: Data sources were researched by this author through PubMed, CINAHL,
and Cochrane in the years 2017 and 2018. Key words used included “Sinusitis” (MeSH),
“Herbal”, “Rhinitis”, and “BNO 1016” (Sinupret). Each article was selected based on its
relevance to Sinupret and sinusitis as well as on having outcomes that would affect the quality of
life of the patient (POEMs). Each study included widely-accepted statistical analyses like pvalues, ANOVA, standard deviations, numbers needed to treat (NNT), t-tests, and post-hoc
sensitivity analyses.
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TABLE 1: DEMOGRAPHICS AND CHARACTERISTICS OF INCUDED STUDIES
STUDY

TYPE

AGE
(yr)
1875

INCLUSION
CRITERIA
ARS (acute
rhinosinusitis)
with ≥ 3 main
symptoms, MSS
(symptom score)
classified as
moderate to severe

EXCLUSION
W/
CRITERIA
D
Pts who were treated 11
with corticosteroids/
abx within 4 weeks of
trial, use of “common
cold” medication
within 7 days of trial,
pregnant/lactating
women, pts with
kidney, liver,
neurological/psych
distress

INTERVENTIONS

RCT

#
PTS
589

Jund et al.,
20153

Palm et al.,
20176

RCT

929

1875

Sinus surgery within
past 2 yrs, CRS due
to allergies, treatment
with systemic or
nasal corticosteroids
within past 4 weeks,
treatment with
decongestant preps,
mucolytics,
antihistamines, and
other “common cold”
OTC meds within 7
days of trial

81
pts

Oral treatment with 2
different doses of
Sinupret in 2 different
groups: 80 mg oral tablet
TID and 160 mg oral
tablet TID (BNO1016herbal combination of
Gentian root, Primula
flower, Sorell herb,
Elder flower, and
Verbana herb) TID x 12
weeks VS. placebo pill
(non-treatment) TID x
12 weeks.

Reden et
al., 20117

RCT

36

2267

Bilateral CRS
(chronic
rhinosinusitis)
without nasal
polyps confirmed
by endoscopy, sxs
present for ≥ 12
weeks, total MSS
(symptom score)
within 6-12 at start
of study, moderate
–severe),
symptoms must
include rhinorrhea
and pain
Pts must have
olfactory
dysfunction as
determined by
ENT –specialist,
must have
sinonasal
inflammation
determined by
endoscopy of the
nasal cavity.

Pts with TDI score
(for olfactory
function) that did not
improve by 3 points
after 7 day
prednisolone
treatment could not
continue in the study.

0

Sinupret oral herbal
supplement: BNO1016
combination of
primrose, gentian root,
verain, elder flower, and
Sorrell 160 mg TID x 2
months POST 1 week of
30 mg Prednisolone QD
VS placebo (160 mg
non-treatment) POST 1
week of 30 mg
Prednisolone QD

Oral treatment with
Sinupret 160 mg
(BNO1016- herbal
combination of Gentian
root, Primula flower,
Sorell herb, Elder
flower, and Verbana
herb) TID x 15 days VS.
placebo pill (nontreatment) TID x 15
days.

Boyle│Sinupret-Herbal Treatment & Sinusitis 5
OUTCOMES MEASURED
Sinupret and AVRS were studied by Jund et al. over a treatment period of 15 days.3 In
the study by Palm et al.6, Sinupret was used in the treatment of CRS over a treatment period of
12 weeks. Reden et al.7 studied Sinupret’s effect on olfactory dysfunction returning after a 7 day
course of corticosteroids over a treatment period of 3 months in patients with CRS. Studies by
Jund et al. and Palm et al. used similar means of measurement outcomes for AVRS/CRS
symptom improvement. The Multiple Symptom Score (MSS), a self-reported symptom rating
per the participants, included five symptoms of rhinorrhea, post-nasal drip, congestion, headache,
and facial pain, each rated on a scale from 0-7 at each visit.6 The total scores were calculated and
averaged and the mean change from baseline in MSS was determined at the end of the treatment
period. The above mentioned studies also measured responders vs. non-responders to treatment
(symptoms cured/improved vs. unchanged/deteriorated compared to previous visit). The final
study by Reden et al. took a different approach and measured Sinupret’s improvement of
olfactory dysfunction in patients with sinusitis using the TDI score (Threshold, Discrimination,
and Identification olfactory testing). This involved the use of “Sniffin Sitcks” in which
participants undertook phenyethanol odor threshold, odor discrimination, and odor identification
testing7. A decrease in TDI scores signals the individual’s olfactory function decreased.
RESULTS
RCT 1- Jund et al. (2015)3: This 589 person study took place in 37 health clinics of
otorhinolaryngology, internal medicine, and family medicine in Germany and attempted to
determine the effectiveness of Sinupret treatment on AVRS symptoms over 14 days. The study
showed statistically significant clinical results. The MSS showed improvement in symptoms by
an average of 7.55 points in the treatment group and only by an average of 6.24 points in the

Boyle│Sinupret-Herbal treatment & Sinusitis 6
placebo group by day 14 of treatment, meaning there was a larger decrease in symptoms (MSS)
in the treatment group compared to placebo. The authors found that this greater decrease of
symptoms with Sinupret was statistically significant at p< 0.0001. This author (Boyle) also
calculated a numbers needed to treat of 10 based on participants being “responders vs. nonresponders” to treatment. On day 14 of treatment, 90.8% of the Sinupret experimental group
were responders to treatment while on the same day only 80.7% of the placebo group were
responders. This NNT signifies that 10 patients would need to be treated with Sinupret for one
more patient to see a positive treatment effect compared to control. The study reports that all data
was analyzed using SAS statistical software and included p-values, standard deviation analyses,
and ANOVAs. Jund et al. also determined that no serious adverse events occurred during the
duration of the study. They reported 9.8% minor adverse events in the Sinupret treated group and
14.1% in the placebo-treated group, indicating a reliable safety profile of the treatment. The
nature of the minor adverse events was not explicitly identified.
Table 2: Reduction in average MSS score from day 0 to day 14
Sinupret (BNO1016) 480 mg

Placebo

Day 0

10.02

9.87

Day 14

2.47

3.63

p-value

<0.0001

<0.0001

Table 3: NNT on day 14 calculated using responders vs. non-responders to treatment
Reee4CER

EER

𝐸𝐸𝑅 − 𝐶𝐸𝑅
𝐶𝐸𝑅

EER-CER

1/ARI

.807

.908

.125

.101

10

p-value

p<0.0002
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RCT 2- Palm et al. (2017)6: This 929 participant study focused on the treatment of CRS with
Sinupret herbal over 12 weeks at 67 centers of otorhinolaryngology, internal medicine, and
family medicine throughout Germany. An important criteria for patient selection was the
determining of CRS for a duration of 12 weeks without nasal polyps confirmed by endoscopy.6
MSS at consecutive visits was also measured as an outcome in this study. The RCT
demonstrated an average decrease in symptoms of 5.4 MSS points for the 480 mg Sinupret
treatment group and only a decrease of 4.0 MSS points for the placebo group at week 8 with a pvalue of p<0.0015. NNT could not be calculated because data were non-dichotomous and
presented in continuous forms. P-values, ANCOVAs, and a post-hoc sensitivity analysis were
used to determine significance of data. Safety profiles of the two different doses of Sinupret were
compared to placebo. No serious adverse events (SAEs) were reported, but the study did find
minor to moderate AEs in 4.4% of the Sinupret group and 3.9% in the placebo group.6 The most
commonly reported AEs in all three groups were abdominal pain, diarrhea, and headache. The
relative similarities between the AEs found between the groups indicates a reliable safety profile
of Sinupret treatment.
Table 4: Reduction in average MSS in chronic rhinosinusitis over 12 weeks
Sinupret 480mg

Placebo

Day 1

10.7

10.8

Week 12

5.3

6.8

p-value

p=0.0015

P=0.0015
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RCT 3- Reden et al. (2011)7: This 36 person study took place at the Taste Clinic at the
University of Dresden Medical School in Germany. It evaluated the effects Sinupret had in
improving olfactory function following a 7 day course of prednisolone in patients with CRS and
coinciding olfactory dysfunction. Olfactory function was measured via TDI score prior to and
after treatment with Prednisolone and then after treatment with Sinupret vs placebo at the 2
month mark. A higher TDI score is indicative of improved olfactory function. The study
determined that the mean decrease in TDI was 8.4 points in the placebo group-indicating the
expected worsening of olfactory function after stopping Prednisolone. The TDI score in the
Sinupret treated group was only decreased by 6.8 points – indicating return olfactory
dysfunction, although less symptomatic than in the placebo group. Statistical measures such as pvalues, t-tests, and ANOVA were used; however, the study found that these results were not
statistically significant (p=0.67). No adverse health events were reported by the authors of this
RCT.
Table 5: Average change in TDI score after 2 months
Sinupret 480 mg

Placebo

7 days post prednisolone

27.8

27.4

2 months

21.0

19.0

p-value

p=0.67

p=0.67

DISCUSSION
Sinusitis, both chronic and acute, stands as a major contributor to high health care costs,
decreased quality of life, and missed productivity. It can lead to facial pain, rhinorrhea,
congestion, fatigue, headache, and anosmia; leaving patients feeling unlike themselves. To this
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day, health care providers still have trouble attributing a cause for AVRS and even more so,
CRS. In addition to this there is no gold standard therapy, and the majority of treatment methods
remain symptomatic. The current most effective treatment for sinonasal inflammation is systemic
corticosteroids.8 However, in CRS, the symptoms typically quickly return after cessation and in
AVRS/CRS chronic treatment with oral steroids is not feasible as prolonged steroid treatment is
known to have detrimental adverse effects on the body.

This systematic review evaluated three randomized control studies in which two of the
three showed that Sinupret herbal combination can be used to decrease the symptoms of
AVRS/CRS with statistical significance. Results showed decreased symptom scores (MSS) in
the treatment groups, as well as increased TDI scores compared to placebo-treated groups;
indicating reduction of sinusitis symptoms and improvement in olfactory function with the use of
Sinupret. The percentage of adverse health events that occurred with Sinupret were reported to
be non-severe in nature and infrequent in studies by Jund et al. and Palm et al. They found that
the side effect profile of the herbal remedy was found to be similar, if not improved, compared to
the placebo groups- indicating a dependable safety profile.3,6

Where would Sinupret fit in with the other symptomatic treatments of AVRS and CRS?
In their study, Jund et al. compared Sinupret to intranasal corticosteroids, a popular treatment
recommended by practitioners for sinusitis, which was recently pushed over-the-counter in the
U.S. Noted in their discussion, was the fact that mometasone (Nasonex) intranasal corticosteroid,
had a NNT for AVRS of 11, while Sinupret was found to have a NNT of 10.3 This suggests a
similar clinical profile of the efficacies of the two drugs and a place for Sinupret as an adjunctive
herbal therapy in symptomatic treatment of sinusitis. Many authors also discussed how Sinupret
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and other symptomatic treatment options could potentially allow for the reduction of the overprescribing of antibiotics.3
Despite compelling evidence, the studies reviewed had notable inadequacies. For
example, all three of the studies took place at health centers in Germany and studied German
populations, putting the generalizability of the results into question. Another limitation regarding
the reliability of these studies is the fact that Binorica, the company that manufactures Sinupret,
was the major funding source for the trials and publications, suggesting a possible source of bias.
Other limitations include subjective self-reporting of symptoms and olfactory function by
participants in all three studies, as well as lack of a standard for the level of severity of sinusitis
symptoms required in patients to participate in the studies. The study by Reden et al., is not as
robust in showing the effects of the intervention as the other two RCTs due to the fact that it only
studied a sample size of 36 and did not find clinically significant data. Studies by Palm et al. and
Jund et al. saw significant results with large sample sizes, indicating robust, more generalizable
results. Despite some downfalls, the results found by Jund et al. and Palm et al. are promising
and suggest that Sinupret’s herbal combination could be considered as an adjunct in the
treatment of sinonasal diseases through its proposed mechanism of suppressing inflammation,
mucus production, and pathogen growth.
CONCLUSION
This systematic review offered insight into three studies using an herbal oral
combination, Sinupret, for the treatment of sinusitis. Due to the thorough nature, large population
size, and clinically significant results of two of the studies,3,6 it was determined that Sinupret is
an effective treatment when compared to placebo, and worthwhile for patients to attempt in the
treatment of sinusitis. It was found to have similar efficacy to an intranasal corticosteroid in
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reducing inflammatory symptoms.3 The common cold may never have a “gold standard”
treatment due to many different and undefinable etiologies, but further pharmaceutical research
is being conducted to discover ways to combat the symptoms of AVRS/CRS that affect so many
Americans every day. This will ultimately allow less health care dollars spent and less missed
productivity days. Herbal medicine is increasingly gaining attention with new research
developing for its use in many different disease states; from psychological disorders, to diseases
of the bowel and bladder, to sinusitis.9 Although research efforts should be continued, Sinupret
presents itself as an effective and safe option to reduce symptoms and recover more rapidly from
sinonasal diseases.
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